REGULATION BRIEFING

FDA Foreign Inspections and PreCheck: Tougher Scrutiny Abroad, a Fast Lane at Home

FDA now inspects most drug plants in India and China without warning, while its PreCheck pilot gives new US plants early review. Together, FDA foreign inspections and PreCheck raise the bar for ex-US suppliers and shorten the path for new US capacity, with the biggest effects on Indian and Chinese API makers, CDMOs and the sponsors who audit them.

FDA foreign inspections and PreCheck: latest updates

FDA foreign inspections and PreCheck at a glance

Full nameFDA expanded unannounced foreign inspections (announced 6 May 2025) and the FDA PreCheck Pilot Program (launched 1 February 2026)
RegionUnited States, covering every site that supplies the US
ThemeRegulation & Quality
Legal statusIn force as agency policy and a pilot program
ImplementationApplying
Key datesUnannounced foreign inspections expanded from May 2025; first PreCheck cohort selected 29 June 2026
ScopeAbout 3,000 foreign inspections a year in more than 90 countries; PreCheck covers new US facilities only
Main leversUnannounced, shorter foreign inspections; early FDA review of new US plants; higher fees for foreign facilities
Who is impactedEx-US API and finished-dose sites, especially in India and China; CDMOs building new US plants; sponsors that audit foreign suppliers
Policy uncertaintyLow: the pace of unannounced inspections and timing of future PreCheck cohorts are still open
PharmaSource Score280 (rank 6)
Impact 4, Reach 7, Likelihood 10
Download the PharmaSource Regulatory Radar

What FDA foreign inspections and PreCheck are

FDA foreign inspections and PreCheck are two halves of one policy: tougher oversight of plants abroad and a faster route for new plants at home. Both follow Executive Order 14293 of May 2025 on domestic production of critical medicines.

  • Unannounced foreign inspections. On 6 May 2025, FDA said it would expand unannounced inspections beyond its India and China pilot. In fiscal 2023, nearly 90% of foreign inspections were preannounced, while US plants get no notice.
  • Independent investigators. FDA said investigators can refuse travel and lodging arranged by the companies they inspect.
  • PreCheck phase 1. A new US plant shares facility design, qualification and quality system plans with FDA through a Type V Drug Master File during construction.
  • PreCheck phase 2. Pre-submission meetings resolve manufacturing issues and bring forward FDA’s review of chemistry, manufacturing and controls.
  • Higher foreign fees. Under GDUFA IV, the extra fee for foreign facilities rises from $15,000 to $25,000.

PreCheck applies only to new US facilities, and FDA estimates it could save participants up to 14 months.

Where FDA foreign inspections and PreCheck stand

Both halves of the policy are running. Unannounced visits are now the norm in India and China, and the first PreCheck plants are in early review.

  • 5 May 2025: The President signs Executive Order 14293 on domestic production of critical medicines.
  • 6 May 2025: FDA expands unannounced foreign inspections.
  • 1 February 2026: FDA launches the PreCheck pilot.
  • 1 March 2026: PreCheck applications close, with more than 80 companies applying.
  • 29 June 2026: FDA selects Amneal, Cellares, Eli Lilly, Fujifilm Biotechnologies, Kriya Therapeutics, Kyowa Kirin and Regeneron.
  • 30 September 2026: Fiscal 2026 ends, with most India and China inspections unannounced.
  • Next: Future PreCheck cohorts, with no date set.

What FDA foreign inspections and PreCheck mean for manufacturing and outsourcing

FDA foreign inspections and PreCheck raise the cost of being an unprepared foreign site and lower the cost of building a new US one. FDA’s Elizabeth Miller said the year’s main focus has been equality between domestic and foreign oversight.

  • Indian and Chinese sites. Inspection readiness becomes a permanent state. India drew 20 of the 45 drug warning letters sent to Asia-Pacific plants in fiscal 2026.
  • Other ex-US CDMOs. Unannounced visits are spreading beyond India and China, and foreign sites pay higher FDA fees.
  • CDMOs building in the US. Two of the seven PreCheck plants belong to CDMOs: Fujifilm’s $3.2bn Holly Springs site and Cellares’ Bridgewater cell therapy facility.
  • US sites too. US-based companies received 72% of fiscal 2026 drug warning letters, so scrutiny at home is rising as well. Under GDUFA IV, US sites can also request surveillance inspections.
  • Sponsors. Supplier audits now have to assume no notice. Past enforcement under the India and China pilot included import alerts and applications held up by inspection findings.

For outsourcing leaders, FDA foreign inspections and PreCheck make a partner’s inspection history and quality maturity part of the commercial decision, alongside price and capacity.

Why supporters back FDA foreign inspections and PreCheck

“The FDA is taking bold steps to bring it back.”

Marty Makary, FDA Commissioner, on manufacturing, at the launch of PreCheck

Lawmakers, regulators and domestic manufacturers back FDA foreign inspections and PreCheck for three reasons:

  • A level playing field. Lawmakers had long argued that advance notice for foreign plants was unfair to US manufacturers, which get no warning.
  • Finding real problems. Even with weeks to prepare, foreign sites showed deficiencies more than twice as often as domestic ones.
  • Supply security. Quality issues and manufacturing delays caused 42% of new drug shortages from 2022 to 2024. PreCheck aims to get new US capacity running sooner.

Criticisms of FDA foreign inspections and PreCheck

“Why would you bother if you have an alternative?”

Marta Wosińska, Senior Fellow, Brookings Institution, on FDA staff retention, speaking at CDMO Live Americas 2026

The main concern is whether FDA has the people to deliver. At CDMO Live Americas 2026, PBOA president Gil Roth said new inspectors now train for six weeks at a computer, against roughly 18 months of shadowing before. GDUFA IV adds no new staff, and Wosińska warned that few veterans remain to train anyone.

Other concerns:

  • A narrow pilot. PreCheck excludes expansions, tech transfers and upgrades of existing sites, and it cannot replace product-specific pre-approval inspections.
  • Few places. Seven plants were chosen from more than 80 applicants.
  • Unclear commitments. Participants pledge to manufacture at the site for three years after approval, and FDA has not said what happens if they cannot.
  • Practical limits abroad. Lawyers flagged the difficulty of scaling surprise inspections and open questions about coordination with foreign authorities.

What’s next for FDA foreign inspections and PreCheck

  • More PreCheck cohorts. FDA has not set a date, and whether it opens the program to expansions will decide its reach.
  • Surprise visits beyond Asia. How fast unannounced inspections reach Europe and other regions.
  • FDA resources. User fee reauthorization under PDUFA VIII and GDUFA IV sets how many inspectors FDA can field.
  • AI in inspections. Quality leaders such as Bimeda’s Colin Baker are already preparing teams for inspectors who arrive with their own AI tools.
  • Our score. The PharmaSource Regulatory Radar ranks FDA foreign inspections and PreCheck sixth of 39 policies, with a score of 280.

Related articles

Tracking global policies and their impact on biopharma manufacturing
REGULATORY RADAR
Full tracker of regulation changing biopharma manufacturing and supply.
Free to access and updated daily.